therapeutics

Study reveals candidate targets for anti-retroviral therapeutics

The increased frequency of drug resistance in isolates of the AIDS virus, HIV, makes identification of new antiviral targets an urgent necessity. Host genes required to support the replication of HIV are a potential source of such novel targets, but relatively few appropriate target genes have been identified in animal cells thus far. A new study, conducted by Dr. Suzanne Sandmeyer and colleagues...

Anthrax inhibitor counteracts toxin, may lead to new therapeutics

Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments. The novel approach used to neutralize anthrax toxin could be applied in designing potent therapeutics for a variety of pathogens and toxins, according to the researchers. <...

Nano-particles effective in killing cancer with one-two punch of chemotherapeutics

Research studies, based at the University of Pennsylvania, demonstrate that biodegradable nano-particles containing two potent cancer-fighting drugs are effective in killing human breast tumors. The unique properties of the hollow shell nano-particles, known as polymersomes, allow them to deliver two distinct drugs, paclitaxel, the leading cancer drug known by brand names such as Taxol, and doxo...

therapeutics at Biology Products

GPCR SpliceArray Service from ExonHit Therapeutics Inc.

Description:The binding specificity and signaling of the members of the GPCR family are known to be modified by alternative splicing--which has important implications for drug research. With GPCR SpliceArrays you can perform a classical expression profiling and at the same time detect the different alternatively spliced forms of the gene that are expressed in the samples under study. The GPCR SpliceArray mon...
Company:ExonHit Therapeutics Inc.

Apoptosis Pathway SpliceArrays from ExonHit Therapeutics Inc.

Description:Alternative Splicing plays an important role in the regulation of signaling pathways involved in apoptosis and cell death. Splice variants have been reported that affect both the activation and inhibition of defined apoptotic pathways. With Apoptosis and Cell Death SpliceArrays you can perform a classical expression profiling and at the same time detect the different alternatively spliced forms...
Company:ExonHit Therapeutics Inc.

Custom Splice Arrays from ExonHit Therapeutics Inc.

Description:Through its SpliceArray service, ExonHit can design custom microarrays to detect alternative splicing events starting with your gene list. Proprietary algorithms are used to identify splice events and design microarray probes from high quality, spliced cDNAs aligned to the human genome. Each splice event contained in a custom SpliceArray is profiled with a patent protected combination of six exo...
Company:ExonHit Therapeutics Inc.

Ion Channel SpliceArray Service from ExonHit Therapeutics Inc.

Description:The binding specificity and signaling of the members of the GPCR family are known to be modified by alternative splicing--which has important implications for drug research. With GPCR SpliceArrays you can perform a classical expression profiling and at the same time detect the different alternatively spliced forms of the gene that are expressed in the samples under study. The GPCR SpliceArray mon...
Company:ExonHit Therapeutics Inc.

Microarray expression profiling service from ExonHit Therapeutics Inc.

Description:SpliceArray Services is a microarray service provider that supports industrial and academic researchers. We are a Certified Servive Provider of Agilent, and we provide expression profiling services on all Agilent catalogue arrays. Gene expression reports are delivered via CD....
Company:ExonHit Therapeutics Inc.

More>>

therapeutics at Biology Technology

Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO

Proventiv was founded in S...

therapeutics at Medicine News

VBI Provides Potential Targets to Diabetes Therapeutics

Virginia Bioinformatics Institute (VBI) Assistant Professor Biswarup Mukhopadhyay has provided important information for researchers designing drugs for type 2 diabetics in the// December 22, 2006, Journal of Biological Chemistry. The information should in time help researchers to identify potential targets for docking inhibitors that will slow down, but not fully eliminate, the body'...

CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG

Cell Therapeutics Inc (Seattle WA) has agreed to pay the US $10.5 millon to resolve allegations of the company's alleged illegal marketing// of the anti-cancer prescription drug Trisenox, the US Justice Department announced earlier this month. According to the government's complaint, CTI promoted the drug for various uses that were unapproved by the US Food & Drug Administration (FDA)...

therapeutics at Medicine Products

Manual of Neurologic Therapeutics, 7th Ed.

Description:This easy-to-navigate reference provides clear, current, clinically proven recommendations for diagnosis and treatment of neurologic disorders....
Company:Skyscape, Inc.

therapeutics at Medicine Technology

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

PHILADELPHIA, July 3, 2007 ? Researchers in Slovakia havebeen able to derive mesenchymal stem cells from human adipose, orfat, tissue and engineer them into “suicide genes” that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack smalltumor metastases that evade current detection techniques andtreatments, the researchers...

More>>